Herein, FLT3 has become an outstanding therapeutic target for AML therapy, guiding the development of various small molecule inhibitors of FLT3, such as Lestaurtinib, Midostaurin, and Quizartinib. The gene discussed is FLT3; the disease is acute myeloid leukemia.